Marnetegragene autotemcel is under clinical development by Rocket Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Marnetegragene autotemcel’s likelihood of approval (LoA) and phase transition for Leukocyte Disorders (White Blood Cell Disorders) took place on 09 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Marnetegragene autotemcel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Marnetegragene autotemcel overview
RPL-201 is under development for the treatment of leukocyte adhesion deficiency (LAD) type 1. The therapeutic candidate constitutes patient-derived hematopoietic stem cells modified with a lentiviral vector containing the CD18 gene. It is administered through intravenous route. It acts by targeting integrin beta 2.
Rocket Pharmaceuticals overview
Rocket Pharmaceuticals (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on
Quick View Marnetegragene autotemcel LOA Data
|Highest Development Stage|